Royalty Report: Drugs, Biotechnology, Disease – Collection: 28782


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Disease
  • HIV / AIDs
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28782

License Grant
The Canadian Licensee acquired an exclusive world wide license, from a Japanese Licensor, for a new drug candidate for the treatment of HIV infection.
License Property
The hNM01 monoclonal antibody that was first discovered and patented by the Licensor.  The antibody has the potential ability to deactivate the HIV virus which may lead to a delay in the development of AIDS in HIV-infected individuals. Licensee will commence the production of hNM01 for continued Phase I/II clinical development of the hNM01 antibody.
Field of Use
The Licensee will continue the development of these antibodies internally and/or in conjunction with a suitable licensing partner.

IPSCIO Record ID: 139546

License Grant
The Canadian Company reacquired the 50% interest in the Antibody 1F7 acquired by Licensor.
License Property
The monoclonal antibody 1F7 has several important effects on both humoral (antibody-mediated) and cellular immunity mechanisms  that make it an ideal candidate for an HIV therapy.  The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T-cells activated in HIV-1 infection.  Immunol Cell Biol 78(1), 20-7.
Field of Use
This agreement pertains to the drug industry related to its use as a therapeutic for the prevention and treatment of HIV infection.

IPSCIO Record ID: 26075

License Grant
The Canadian Licensee was granted an exclusive license to use and sublicense the technology characterized as 'Antibody 1F7' and to make or have made licensed products in all countries of the world in which the Licensor has patent rights, and to sell licensed products worldwide.
Field of Use
AIDS Project 1F7 The monoclonal antibody, is a new approach for treating HIV infection aimed at resetting the body's immune system so that it can continue to fight the AIDS virus even as the virus mutates. It not directed against HIV itself but is able to stimulate the immune system directly.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.